Thibault A - Search Results

1

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.

Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. Among authors: thibault a. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794

2

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.

Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Among authors: thibault a. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>3.0.co;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.

3

Acute renal toxicity associated with suramin in the treatment of prostate cancer.

Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC, Reed E, Sartor O. Figg WD, et al. Among authors: thibault a. Cancer. 1994 Sep 1;74(5):1612-4. doi: 10.1002/1097-0142(19940901)74:5<1612::aid-cncr2820740519>3.0.co;2-q. Cancer. 1994. PMID: 8062193

4

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Dawson NA, et al. Among authors: thibault a. Cancer. 1995 Aug 1;76(3):453-62. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. Cancer. 1995. PMID: 8625127 Clinical Trial.

5

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.

Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Among authors: thibault a. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.

6

Phase I study of phenylacetate administered twice daily to patients with cancer.

Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Thibault A, et al. Cancer. 1995 Jun 15;75(12):2932-8. doi: 10.1002/1097-0142(19950615)75:12<2932::aid-cncr2820751221>3.0.co;2-p. Cancer. 1995. PMID: 7773944 Clinical Trial.

7

A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.

Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, Tompkins AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, et al. Thibault A, et al. Cancer Res. 1994 Apr 1;54(7):1690-4. Cancer Res. 1994. PMID: 8137283 Clinical Trial.

8

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Figg WD, et al. Among authors: thibault a. Arch Intern Med. 1994 May 9;154(9):1023-5. Arch Intern Med. 1994. PMID: 8179445

9

In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.

Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. Figg WD, et al. Among authors: thibault a. Anticancer Drugs. 1994 Jun;5(3):336-42. doi: 10.1097/00001813-199406000-00012. Anticancer Drugs. 1994. PMID: 7919459

10

Anaphylactoid reaction with suramin.

Thibault A, Figg WD, Cooper MR, Prindiville SA, Sartor AO, Headlee DJ, Myers CE. Thibault A, et al. Pharmacotherapy. 1993 Nov-Dec;13(6):656-7. Pharmacotherapy. 1993. PMID: 8302692

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters